A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Latest Information Update: 01 Aug 2024
At a glance
- Drugs VC 005 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Jiangsu Vcare Pharmatech
Most Recent Events
- 29 Jul 2024 Status changed from recruiting to completed.
- 22 Aug 2023 New trial record
- 16 Aug 2023 Status changed from not yet recruiting to recruiting.